Physician profile
Muntasir Khaled
NPI 1922507003
$4,658.72
in general payments reported to CMS, 2019-2025
22 companies · $1,006 in 2025
The $1,006 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $68.22 · 2022: $2,208 · 2023: $683 · 2024: $693 · 2025: $1,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,382.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seapearl East, INC | $1,236.43 | 2022 | |
| Kerecis Limited | $955.35 | 2023-2025 | Kerecis Surgiclose, Kerecis Graftguide, Kerecis Omega3 Surgiclose |
| Stryker Corporation | $572.43 | 2022-2025 | Am, Augment Injectable, Ortholoc 2 Lapifuse |
| Smith+Nephew, INC. | $512.39 | 2022-2024 | Collagenase Santyl, Renasys Go V2 Home |
| Treace Medical Concepts, INC. | $509.06 | 2022-2024 | |
| Nevro Corp. | $126.53 | 2023 | Senza |
| Abbvie INC. | $121.08 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.66 | 2023-2024 | Xifaxan, Trulance |
| Corcept Therapeutics | $97.70 | 2021-2023 | Korlym |
| Paratek Pharmaceuticals, INC. | $87.31 | 2024-2025 | Nuzyra |
| Astrazeneca Pharmaceuticals Lp | $75.97 | 2022 | |
| Lilly USA, LLC | $45.63 | 2023 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $37.21 | 2024 | Rexulti |
| US Implant Solutions, LLC | $29.10 | 2024 | |
| Bioventus LLC | $29.03 | 2024 | Gelsyn-3 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $19.23 | 2025 | Senza |
| Cashflow Solutions, LLC | $17.76 | 2024 | Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White |
| Averitas Pharma INC. | $17.75 | 2024 | Qutenza |
| Urgo Medical North America, LLC | $17.60 | 2024 | Urgoclean Ag |
| Scilex Pharmaceuticals INC. | $15.11 | 2023 | Ztlido |
| Novo Nordisk INC | $14.33 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muntasir Khaled listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.